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Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by intraneuronal
deposition of the nuclear TAR DNA-binding protein 43 (TDP-43) caused by unknown mechanisms. Here, we studied TDP-43
in primary neurons under different stress conditions and found that only proteasome inhibition by MG-132 or lactacystin
could induce significant cytoplasmic accumulation of TDP-43, a histopathological hallmark in disease. This cytoplasmic
accumulation was accompanied by phosphorylation, ubiquitination and aggregation of TDP-43, recapitulating major
features of disease. Proteasome inhibition produced similar effects in both hippocampal and cortical neurons, as well as in
immortalized motor neurons. To determine the contribution of TDP-43 to cell death, we reduced TDP-43 expression using
small interfering RNA (siRNA), and found that reduced levels of TDP-43 dose-dependently rendered neurons more
vulnerable to MG-132. Taken together, our data suggests a role for the proteasome in subcellular localization of TDP-43, and
possibly in disease.
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Introduction
Amyotrophic lateral sclerosis (ALS) [also referred to as Lou
Gehrig’s disease] is the most frequent form of motor neuron
disease and is characterized by rapidly progressive degeneration of
upper and lower motor neurons. ALS often leads to death within
three years of diagnosis [1,2]. Unfortunately, there is no cure
available. In comparison, frontotemporal lobar degeneration
(FTLD) is a heterogeneous group of neurodegenerative disorders,
clinically characterized by behavioral changes and/or language
abnormalities, which may also be accompanied by motor
symptoms, such as parkinsonism [3,4] or ALS [3,5]. FTLD is
the second most common form of dementia presenting before the
age of 65 [6]. In contrast to Alzheimer’s disease, memory deficits
are less common in FTLD [7,8]. As for ALS, no therapy or cure is
available for FTLD.
Histopathologically, FTLD can either present with inclusions
consisting of fibrillary aggregates of the microtubule-associated
protein tau, or inclusions which are tau-negative, but stain with
antibodies to ubiquitin (FTLD-U) [9]. The FTLD-U cases can be
further categorized based on the protein content of the
ubiquitinated inclusions [5]. Hence, FTLD-U cases with inclusions
consisting of the protein TAR DNA-binding protein 43 (TDP-43)
are termed FTLD-TDP, in contrast to FTLD-tau with tau
inclusions, FTLD-FUS with inclusions containing fused in
sarcoma (FUS) protein, and a smaller group of cases with deposits
of unknown content termed FTLD-ubiquitin proteasome system
[10]. Similar ubiquitin-positive inclusions are also found in motor
neurons and some other neurons in ALS, and can contain either
aggregated TDP-43 [11,12] and/or FUS [13]. Furthermore,
TDP-43 pathology is also observed in a proportion of patients with
other neurodegenerative disorders such as Alzheimer’s disease, but
in a restricted anatomical distribution and at a much lower density
[14]. In FTLD-TDP and ALS, the cytoplasmic accumulation of
TDP-43 is accompanied by loss of staining of the nucleus,
suggesting that loss of its nuclear function may contribute to the
pathogenesis of the disease. The mechanisms, however, underlying
this redistribution from the nuclear to the cytoplasmic compart-
ment, as well as the cellular consequences, remain to be
elucidated.
TDP-43 is an ubiquitous nuclear protein of 414 amino acids
and 43 kD that is encoded by the gene TARDBP on human
chromosome 1. It was first identified as a binding partner of the
human immunodeficiency virus TAR DNA element [15].
Although the normal biological functions of TDP-43 are not yet
fully understood, it has been implicated in transcriptional
repression, exon splicing, and possibly miRNA generation, cell
cycle regulation and apoptosis [16].
A pathogenic role for TDP-43 in disease is supported by the
identification of mutations in TARDBP in familial and sporadic
ALS [17,18,19,20,21,22,23]. To date, 29 different missense
mutations have been identified in TARDBP. In FTLD, where
40% of patients have a family history of neurological disease, other
multiple chromosomal loci have been revealed [24]. Here,
pathogenic mutations in the tau-encoding MAPT gene were the
first to be found in familial forms of FTLD-tau [25,26,27]. This
assisted in the development of both cell culture and animal models
to investigate tau-related pathomechanisms [28,29,30,31]. Muta-
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FTLD plus ALS [32,33,34,35]. Other more frequent pathogenic
mutations have been described in genes including PGRN [36,37],
VCP [38] and CHMP2B [39]. Most of these are associated
histopathologically with TDP-43 containing inclusions, however,
the mechanistic link between these mutations and TDP-43
deposition is not yet fully understood. Cell culture, as well as
yeast and animal models have provided insights into TDP-43
pathology [17,18,20,40,41,42]. However, neuronal cell culture
models that recapitulate the TDP-43 pathology in FTDL-TDP
and ALS are limited.
Proteins that are targeted for degradation are enzymatically
tagged with ubiquitin, which promotes disintegration by the
proteasome machinery [43]. Pathological protein aggregates are
frequently surrounded by proteasomes and lysosomes, however,
these fail to fully remove the deposits [44,45]. In addition,
proteasome activity declines with age, and is reduced even more so
in neurodegenerative disorders such as Alzheimer’s or Parkinson’s
diseases [43]. However, it remains unknown, if this degradative
dysfunction is the cause or the result of neurodegeneration [43,46].
Reduced proteasome activity results in reduced solubility and
fragmentation of TDP-43 in lymphoblastoid cells isolated from
ALS patients [18,20]. Here, we studied the effects of proteasome
inhibition induced by benzyloxycarbonyl-l-leucyl-l-leucyl-l-leuc-
inal (MG-132) or lactacystin on TDP-43 in neurons. We show that
impairing proteasome activity is sufficient to induce cytoplasmic
accumulation and aggregation of TDP-43 in primary hippocam-
pal and cortical neurons, as well as an immortalized motor neuron
cell line NSC-34.
Results
Proteasome inhibitors, but not other stressors induce
cytoplasmic accumulation of TDP-43 in primary neurons
Redistribution of TDP-43 from the nucleus to the cytoplasm is a
characteristic feature found in neurons of brain and spinal cord
sections from FTLD-TDP and ALS patients [11] (Fig. 1A). The
cellular/molecular event(s) that lead to aberrant distribution of
TDP-43 in disease remains unknown. It may result from toxic up-
stream events that directly affect subcellular localization of TDP-
43, it may be associated with cell death, or it may result from the
failure of physiological processes that regulate the subcellular
distribution of TDP-43. To test this, we treated mature primary
murine neurons with a battery of toxins and inhibitors to impair
different cellular processes, which also reflect different modes of
toxicity implicated in neurodegeneration. The treatments included
induction of apoptotic caspase signalling (staurosporine), excito-
toxicity (N-Methyl-D-aspartic acid (NMDA)), oxidative stress and
mitochondrial damage (H2O2), proteasome inhibition (MG-132,
lactacystin) and ER stress (thapsigargin (TG), tunicamycin (TM)).
Following treatment, the subcellular distribution of TDP-43 was
determined immunocytochemically, complemented by Western
blot analysis. Interestingly, only proteasome inhibition with MG-
132 or lactacystin resulted in a pronounced change in TDP-43
localization with cytoplasmic accumulation, while TDP-43
remained primarily in nuclei of neurons exposed to staurosporine,
NMDA, H2O2,T Go rT M( Fig. 1B). All substances caused a
similar degree of cell death at the chosen concentrations, but had
profoundly different effects on the neurons. Accordingly, Western
blot analysis revealed similar phosphorylation of H2AX, a non-
specific marker of cell death (Fig. S1A), while only MG-132 and
lactacystin induced heat shock protein 70 (Hsp70) expression and
widespread ubiquitination (Fig. S1B).
Proteasome inhibition increases cytoplasmic TDP-43 in
primary neurons
Impaired proteasome function has been implicated in neurode-
generative disorders including FTLD-U and ALS, resulting in
decreased clearance of mislocalized and misfolded proteins [43].
Given that only proteasome inhibition induced cytoplasmic
accumulation of TDP-43 in primary neurons under our experi-
mental conditions (Fig. 1B), we analysed these changes in more
detail. Therefore, we treated primary hippocampal and cortical
neurons, as well as the motor neuron cell line NSC-34 with the 26S
proteasome inhibitor, MG-132, and assessed TDP-43 re-distribu-
tion, accumulation and aggregation. First, mature hippocampal
primary neurons at 20 days in vitro (DIV) were treated with 5 mM
MG-132 for 24 to 60 hours and analyzed by immunocytochemistry.
While TDP-43 localized strictly to the nucleus in vehicle-treated
controls, as observed by overlay with DAPI staining, proteasome
inhibition resulted in staining of TDP-43 in the cytoplasm together
with a reduction in nuclear TDP-43 staining (Fig. 2A and B). In a
subset of cells with accumulation of TDP-43 in the cytoplasm
following proteasome inhibition, we observed focal accumulations
that stained intensely with antibodies to TDP-43, suggestive of
aggregate formation (Fig. 2C). Proteasome inhibition may also
induce re-localization of other nuclear proteins besides TDP-43.
Therefore, we stained for the closely related nuclear factors hnRNP
A1, hnRNP A2/B1 and FUS. In contrast to TDP-43, hnRNP A1,
hnRNP A2/B1 and FUS all remained in the nucleus of MG-132
treated cells (Fig. 2D). Hence, proteasome inhibition did not affect
the localization of nuclear proteins in general.
While 5 mM MG-132 treatment already resulted in the appear-
ance of cytoplasmic TDP-43 after 12 hours, first signs of degener-
ation only occurred after 36 hours, as determined by fragmented
neuronal b3-tubulin staining in processes (Fig. 3A). Counting of
neurons revealed that 5 mM MG-132 significantly reduced numbers
of viable attached cells only after 36 hours (Fig. 3B). Furthermore,
we determined the toxicity of MG-132-mediated proteasome
inhibition by propidium iodine (PI) uptake, a measure of cell death
frequently used in neurons [47,48]. While both vehicle and MG-132
treatment showed similar numbers of PI-positive cells after 16 hours,
this was significantly increased with MG-132, but not vehicle,
treatment after 36 hours, suggesting late but not early toxicity
(Fig. 3C and D). Taken together, treatment of cultured primary
neurons with the proteasome inhibitor MG-132 resulted in early
cytoplasmic accumulation of TDP-43 followed by late cell death.
Proteasome inhibition results in re-distribution of TDP-43
in primary cortical neurons
Next, we addressed the subcellular distribution of TDP-43 in
cortical neurons following MG-132 treatment. Nuclei of MG-132
and vehicle treated primary cortical neurons were separated from
cytoplasmic fractions at different time points by sequential
extraction [49] (Fig. 4A and B). Consistent with its physiological
localization, TDP-43 was predominantly found in the nuclear
fraction of vehicle-treated control cells at all time points (Fig. 4C,
top). Similarly, TDP-43 was abundant in the nuclear fraction after
6 hours of incubation with MG-132. However, levels of nuclear
TDP-43 progressively decreased after 12 hours of treatment with
MG-132, and were undetectable after 60 hours (Fig. 4C, top). In
parallel to the nuclear decrease, TDP-43 was increasingly
recovered in cytoplasmic fractions until 12 hours of treatment
with MG-132. Interestingly, TDP-43 then also progressively
decreased in the cytoplasmic fraction after 24 and 36 hours, and
was hardly detectable at 60 hours (Fig. 4C, bottom). Since there
was no obvious difference in the intensity of cytoplasmic TDP-43
TDP-43 and Proteasome Inhibition in Neurons
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even later (Fig. 2D), we hypothesized that the late decrease in
both nuclear and in particular cytoplasmic TDP-43 revealed by
the sequential extraction (Fig. 4C) may reflect increasing
insolubility of TDP-43, which would therefore not be extracted
by the buffer used to recover cytoplasmic proteins. Therefore, we
resuspended pellets from the previous fractions in stringent urea
buffer (Fig. 4D). Consistent with an increased insolubility, the
amount of TDP-43 in the urea extracts increased with treatment
duration. In addition, higher molecular weight aggregated forms
of TDP-43 appeared together with fragments, as revealed by long
exposure of membranes (Fig. 4D, bottom). Taken together,
MG-132 treatment of cortical neurons resulted in cytoplasmic
accumulation of TDP-43, which eventually became insoluble.
Increased TDP-43 insolubility, phosphorylation and
ubiquitination upon proteasome inhibition in primary
neurons
In disease, TDP-43 becomes increasingly insoluble, is
aberrantly phosphorylated and shows pronounced ubiquitination
[11]. Therefore, we addressed the solubility of TDP-43, as well
Figure 2. Proteasome inhibition results in cytoplasmic accumulation of TDP-43, but not hnRNP A1, hnRNP A2/B1 or FUS in primary
hippocampal neurons. (A) TDP-43 expression is restricted to the nucleus (broken line) in vehicle (DMSO) treated primary hippocampal neurons,
while being absent from the cytoplasm (open arrowhead). Treatment with 5 mM MG-132 for 12 hours, however, results in cytoplasmic accumulation
of TDP-43 (arrowhead), together with reduced nuclear staining. The cellular integrity appears similar in vehicle and MG-132 treated cells, as shown by
staining for cytoskeletal neurofilament (NF). Cell nuclei are counterstained with DAPI. Scale bar, 10 mm. (B) Quantification of nuclear and cytoplasmic
TDP-43 fluorescence staining of vehicle and MG-132 treated primary hippocampal neurons. MG-132 treatment reduces nuclear TDP-43 (Student’s t
test P,0.05; * indicates P,0.01), while cytoplasmic TDP-43 increases markedly (** indicates P,0.001). (C) In a subset of neurons, MG-132 induced
accumulation of TDP-43 in the cytoplasm is accompanied by focal intensive staining in soma and processes, suggestive of aggregate formation
(arrow). Scale bar, 25 mm. (D) While TDP-43 accumulates in the cytoplasm upon MG-132 treatment, the nuclear localization of neither hnRNP A1,
hnRNP A2/B1 nor FUS is affected (open arrowhead) compared to vehicle (DMSO) treated neurons. Nuclei are stained with DAPI. Scale bar, 10 mm.
doi:10.1371/journal.pone.0022850.g002
Figure 1. Proteasome inhibition results in cytoplasmic TDP-43 accumulation in cultured neurons. (A) Example of immunohistochemical
staining for TDP-43 on human frontotemporal lobar degeneration (FTLD) brain and amyotrophic lateral sclerosis (ALS) spinal cord sections. While
TDP-43 is normally in the nucleus (asterisk), it accumulates in cytoplasmic aggregates (arrow), while being depleted from the nucleus in affected
dentate gyrus neurons in FTLD-TDP. Similarly, TDP-43 that is normally in the nucleus of motor neurons (asterisk), accumulates (arrowhead) and forms
cytoplasmic aggregates (arrow) and is depleted from the nucleus in ALS. (B) Primary neurons were treated with vehicle (DMSO) or different
substances and then stained with antibodies to TDP-43 to assess its subcellular distribution, and neurofilament (NF) for cellular integrity. Doses and
treatment times are specified in Materials and methods. TDP-43 localizes primarily to the nucleus upon treatment with H2O2 (oxidative stress), N-
Methyl-D-aspartic acid (NMDA, excitotoxicity), staurosporine (caspase activation), thapsigargin or tunicamycine (both endoplasmic reticulum (ER)
stress). In contrast, proteasome inhibition with lactacystin or MG-132 treatment induces cytoplasmic accumulation of TDP-43 (arrowheads). DAPI
stains nuclei. Representative neurons from three independent experiments are shown.
doi:10.1371/journal.pone.0022850.g001
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neurons following treatment with MG-132. The cells were
extracted at different time points with RIPA buffer followed by
extraction in urea buffer to recover insoluble TDP-43 [50]. In
addition to the characteristic 43kD TDP-43 band, we observed
an additional band of approximately 50kD that is only present in
primary mouse neurons. Treatment with MG-132 resulted in a
progressive decrease in soluble TDP-43, with levels hardly
detectable after 48 hours (Fig. 5A, top). No changes in soluble
TDP-43 were observed with vehicle treatment. Levels of
insoluble 43 kD TDP-43 increased progressively, with highest
levels observed after 36 hours (Fig. 5A, bottom). Western blots
of the urea buffer fractions also reveal increased amounts of
insoluble high molecular TDP-43 species together with lower
molecular weight fragments. Hardly any insoluble TDP-43 was
present in the vehicle treated cells. Consistent with impaired
proteasome activity, treatment with MG-132 induced expression
of Hsp70, which was readily detectable after 12 hours and
thereafter (Fig. 5B). Proteasome inhibition was accompanied by
accumulation of ubiquitinated proteins of decreased solubility
(Fig. 5C). Immunoprecipitation with an antibody to TDP-43
and subsequent detection of Western blots with an antibody to
ubiquitin confirmed the high degree of TDP-43 ubiquitination
following proteasome inhibition (Fig. 5D). Furthermore, we
determined phosphorylation of insoluble TDP-43, with site-
specific antibodies. This revealed increased phosphorylation of
insoluble TDP-43 at serine (S) 403/404 and S409/410 as the
duration of the MG-132 treatment increased (Fig. 5E).
Dephosphorylation confirmed the specificity of the antibodies
used for the respective phospho-epitopes (Fig. 5F). Consistent
with the Western blots, immunocytochemistry with the phos-
phorylation site-specific S403/404 antibody showed pronounced
staining of cytoplasmic TDP-43 in MG-132-treated cortical
neurons, while vehicle-treated control cells showed minimal
staining (Fig. 5G). Taken together, proteasome inhibition in
cortical neurons caused insolubility of TDP-43 in a time-
dependent manner, as well as its phosphorylation and ubiqui-
tination.
Figure 3. Cell death occurrs after TDP-43 alterations in MG-132 treated primary neurons. (A) Staining for neuronal b3-tubulin is similar in
vehicle (DMSO) and MG-132-treated neurons after 12 hours, whereas after 36 hours of treatment the staining reveals fragmentation of tubulin in MG-
132 treated cells, indicating cell death. Scale bar, 50 mM. Representative pictures from at least three experiments are shown. (B) Number of viable
attached primary neurons are similar for up to 24 hours of vehicle and MG-132 treatment, but decline significantly thereafter upon MG-132 exposure
(* indicates P,0.05; n=4). (C) Immunocytochemical staining with antibodies to TDP-43 combined with propidium iodine (PI) and nuclear
counterstaining with DAPI. Cell death is indicated by PI uptake and nuclear staining (arrowheads). Note the cytoplasmic accumulation of TDP-43
upon MG-132 treatment (right panels), and the increased numbers of PI positive neurons after 36 hours of MG-132 exposure (bottom right panel).
Scale bar, 25 mM. (D) Numbers of PI positive neurons are similar after 16 hours of vehicle and MG-132, and 36 h of vehicle treatment, but significantly
increased after 36 hours of MG-132 exposure (Student’s t test P,0.05; n.s., not significant; * indicates P,0.05).
doi:10.1371/journal.pone.0022850.g003
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NSC-43 cells
Neuronal cell lines have been instrumental in studying both
physiological and pathological processes in neurodegeneration
[51]. Therefore, we addressed whether treatment with MG-132
would induce TDP-43 insolubility, similar to that observed in
primary cultured neurons, in immortalized, murine motor neuron
NSC-34 cells [52]. We induced cell cycle arrest with mitomycin C
treatment to synchronize all cells prior to treatment with MG-132.
Mitomycin C treatment alone had no effect on TDP-43 solubility
(data not shown). Proteins were extracted from treated NSC-34
cells based on their solubility, using the same method as described
above for primary cortical neurons [49]. Proteasome inhibition
leads to a moderate decrease in soluble TDP-43 (Fig. S2A). In
parallel, it caused a progressive increase in insoluble TDP-43,
together with the appearance of high molecular weight aggregates.
In comparison, the amount of insoluble TDP-43 in vehicle treated
controls was very low. In contrast to the primary neuronal
cultures, insoluble 25 and 35kD low-molecular weight fragments
were much more abundant in the NSC-34 cells. Similar to the
primary neurons, treatment with MG-132 resulted in a progressive
increase in Hsp70 expression levels after 12 hours, together with a
high degree of protein ubiquitination consistent with proteasome
inhibition (Fig. S2B and C). Next, we counted the number of
viable NSC-34 cells during MG-132 treatment (Fig. S2D). Cell
numbers were comparable with vehicle until 36 hours of MG-132
treatment, and significantly lower numbers were observed only
48 hours after the commencement MG-132 treatment, suggesting
that TDP-43 insolubility precedes cell death.
In addition to the characteristic 43kD band, the insoluble
fractions contained increasing amounts of a 45kD TDP-43
reactive product (Fig. S2A). Consistent with TDP-43 phosphor-
ylation, dephosphorylation with alkaline phosphatase (AP) of the
insoluble fractions from MG-132 treated NSC-34 cells resulted in
a molecular weight shift to 43 kD (Fig. S2E). Furthermore,
immunoprecipitation with a TDP-43 antibody and subsequent
Western blotting with an antibody to ubiquitin showed that TDP-
43 was highly ubiquitinated following MG-132 treatment of NSC-
34 cells (Fig. S2F). Taken together, MG-132 treatment of NSC-
34 cells results in a progressive increase in the insolubility of TDP-
43 associated with phosphorylation and ubiquitination, resulting in
an expression pattern very similar to primary neurons and, more
importantly, FTLD-TDP and ALS.
Reducing TDP-43 levels increases proteasome
inhibition-induced cell death
MG-132 treatment of neurons recapitulated major histopath-
ological findings observed in human ALS and FTLD-TDP. The
question remains, however, whether this is a secondary effect in
cells that eventually die from proteasome inhibition, or if TDP-43
contributes to the cell death following MG-132 treatment. To
address this question, we utilized siRNA-mediated knockdown of
TDP-43 expression in primary cortical neurons, then treated the
cells with MG-132 and determined cell death by PI uptake as
described in [48]. To achieve knockdown of TDP-43 in primary
neurons, we tested four different siRNA constructs together with a
control vector from the MISSION library (Sigma, USA) using
lentiviral expression. Two siRNAs (#560 and #543) mediated
significant knockdown of TDP-43 in primary neurons with siRNA
#560 being more effective than siRNA #543, while control
infections did not alter TDP-43 levels, as shown by immunocy-
tochemistry and Western blotting (Fig. 6A–C). Accordingly,
immunocytochemistry with antibodies to TDP-43 showed reduced
Figure 4. Primary cortical neurons show cytoplasmic accumu-
lation and eventually insolubility of TDP-43 in response to
proteasome inhibition. (A) Scheme of subcellular extraction into
cytoplasmic and nuclear fractions, with subsequent reconstitution of
insoluble proteins in urea buffer. For details see Methods and materials.
(B) Western blotting of representative fractionation with nuclear marker
hnRNP A1 and cytoplasmic marker Gapdh. (C) Subcellular fractionation
of vehicle (DMSO) and MG-132-treated primary cortical neurons over
60 hours. TDP-43 is primarily in the nuclear fraction after 6 to 60 hours
of vehicle treatment. In contrast, nuclear TDP-43 decreased progres-
sively, and increased transiently in the cytoplasmic fraction upon MG-
132 treatment. (D) Insoluble pellets from the cytoplasmic fraction were
extracted with a urea buffer. This shows increasing amounts of
insoluble TDP-43 (arrowhead) during MG-132, but not vehicle
treatment. Long exposure of the Western blot reveals the presence of
both low molecular weight fragments (*) and high molecular weight
aggregates (#) of TDP-43 upon MG-132 treatment. Representative blots
of three experiments are shown.
doi:10.1371/journal.pone.0022850.g004
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22850Figure 5. Progressive insolubility of TDP-43 upon proteasome inhibition in primary cortical neurons. (A) Proteins were extracted from
MG-132 and vehicle (DMSO) treated primary cortical neurons, with RIPA buffer followed by urea extraction of the insoluble pellets. TDP-43
(arrowhead) and its fragments (*) progressively disappear from the RIPA-soluble fractions over 60 hours, whereas no change is observed in vehicle
treated controls. Note the presence of soluble TDP-43 fragments in controls. In parallel, TDP-43 (arrowhead) increased in the insoluble (Urea) fractions
of MG-132 treated neurons together with fragments (*) and high molecular weight aggregates (#). An additional TDP-43 reactive band of
approximately 50kD appears only in primary cortical neurons. (B) Consistent with proteasome inhibition by MG-132, levels of heat-shock protein 70
(Hsp70) increase with time. (C) Similarly, the amount of insoluble highly ubiquitinated proteins increase progressively upon MG-132 treatment. (D)
Immunoprecipitation (IP) with an antibody to TDP-43 and subsequent detection with an antibody to ubiquitin shows the high degree of
ubiquitination of the high molecular weight TDP-43 reactive species (#). Note the 50kD Fc-antibody band (a). (E) Antibodies specific to
phosphorylation sites on TDP-43 (pS403/404 and pS409/410) reveal increasing phosphorylation of TDP-43 over time upon MG-132 treatment.
Representative Western blots from four experiments are shown. (F) Dephosphorylation of urea extracts with alkaline phosphatase (AP) confirms the
specificity of the antibodies to S403/4 and S409/10. Lane 1, urea extract of DMSO-treated neurons treated with AP; lane 2, urea fraction of MG-132-
treated neurons for 36 hours; lane 3, same extract as lane 2 but treated with AP. (G) Similar to the Western blots, immunocytochemical staining with
pS403/404 shows cytoplasmic staining in MG-132-treated neurons, different from DMSO-treated cells.
doi:10.1371/journal.pone.0022850.g005
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compared with controls, with stronger reduction with siRNA
#560 than siRNA #543 expression (Fig. 6A and B). Similarly,
Western blotting showed greater reduction in TDP-43 levels with
siRNA #560, than with siRNA #543 (Fig. 6C). Control infection
did not alter TDP-43 levels. The 4265.0% reduction of TDP-43
levels caused by siRNA #543 did not affect survival of the
neurons, as indicated by similar numbers of PI-positive neurons
compared to non- or control-transfected cells (Fig. 6A and D). In
contrast, the strong reduction of TDP-43 by siRNA #560 reduces
viability with increased numbers (7961.5%) of PI-positive neurons
(Fig. 6A and D).
Consistent with our previous findings, MG-132 treatment
resulted in cytoplasmic re-distribution of TDP-43, with
1761.4% of control cells being PI positive after 16 hours
compared with 1461.3% PI-positive cells with DMSO treatment
(Fig. 6D), consistent with survival rates of non-infected MG-132-
treated neurons (not shown). However, cells with siRNA #543-
mediated knockdown of TDP-43 showed a significantly higher
number (5561.8%) of PI positive cells following MG-132
treatment compared with 1861.5% of PI-positive cells with
DMSO treatment, suggesting increased vulnerability to protea-
some inhibition (Fig. 6D). SiRNA #560-induced TDP-43
knockdown together with MG-132 treatment caused PI uptake
in virtually all cells at 16 hours (Fig. 6D). This suggests that the
level of TDP-43 reduction correlates with cell death after MG-132
treatment. Re-localization of TDP-43 was not affected by the
knockdown, since MG-132 treatment still resulted in cytoplasmic
TDP-43, although staining was much less intense due to the
reduction in its overall levels (Fig. 6E). Taken together, reduced
TDP-43 levels increased cell death induced by MG-132 in primary
neurons.
Discussion
In the present study, we demonstrate that inhibition of the
proteasome in both primary hippocampal and cortical neurons
induces accumulation of the nuclear factor TDP-43 in the
cytoplasm and its progressive insolubility. In addition to the
43kD full-length TDP-43 band, the insoluble fractions contained
increasing amounts of high molecular weight TDP-43-reactive
products, consistent with detergent-stable aggregates. This pattern
of aggregates appears similar to that of insoluble extracts obtained
from FTLD-TDP and ALS tissues [11]. The inclusions in FTLD-
TDP and ALS contain both phosphorylated and ubiquitinated
TDP-43 [11,53,54]. Similarly, using phosphorylation site-specific
antibodies, we show the presence of phosphorylated TDP-43 in
insoluble fractions from MG-132 treated cells, while IP confirmed
ubiquitination of TDP-43. Interestingly, immunocytochemistry of
MG-132-treated neurons shows that phosphorylation of TDP-43
at S403/S404 was significantly increased when TDP-43 localized
to the cytoplasm. Similar to primary neurons, proteasome
inhibition in immortalized murine motor neurons, NSC-34,
resulted in progressive insolubility of TDP-43, with increased
phosphorylation, ubiquitination and fragment formation, demon-
strating their potential as a cell culture model for an ALS-like
TDP-43 pathology. It remains to be determined whether
phosphorylation and/or ubiquitination are directly involved in
the cytoplasmic accumulation of TDP-43, as it has been suggested
for FTLD-TDP and ALS [53], or, alternatively, whether this
occurs after TDP-43 accumulates in the cytoplasm. The latter may
be supported by the finding that TDP-43 phosphorylation is a late
event in a cellular disease model, and therefore not a prerequisite
for its aggregation [55].
In addition to the high molecular weight aggregates of TDP-43,
proteasome inhibition also induced the formation of lower
molecular weight fragments. These fragments were of 25 and
35kD, which is reminiscent of FTLD-U and ALS [11]. It has been
suggested that formation of fragments is a critical step in the TDP-
43 pathology [20,56]. Interestingly, fragments of 35kD and, to a
lesser degree, 25kD were also revealed in vehicle treated cells, but
only became insoluble together with full-length TDP-43 in MG-
132 treated cells, which may suggest that fragmentation alone is
not sufficient to induce insolubility. A second hit such as
proteasome inhibition, appears to be needed to induce insolubility
in our system.
Apart from proteasome inhibitors, additional cell stressors have
been used to reproduce features of TDP-43 pathology in different
cell culture systems. For example, fragmentation of TDP-43 in cell
culture has been induced by staurosporine [55,56] as well as TG
[57]. However, mostly immortalized, non-neuronal cell lines and
mutant forms of TDP-43 have been used. Given the neuronal
pathology, we tested a range of stressors in our primary cell culture
system. Consistent with other studies in cell lines, fragmentation of
TDP-43 occurred under most conditions, and was very prominent
in NMDA-, staurosporine- and H2O2-treated neurons (data not
shown). Interestingly, in our experiments, neither excitotoxicity,
caspase activation, oxidative stress nor ER stress induced
noticeable accumulation of TDP-43 in the cytoplasm. Therefore,
pronounced TDP-43 accumulation in the cytoplasm is, among the
tested cell stressors, a unique feature of proteasome inhibition.
This possibly reflects that the subcellular distribution of TDP-43 is
regulated, at least in part, by the proteasome system. Interestingly,
proteasome inhibition is known to change the subcellular
localization of a range of proteins in processes like centrosome
recruitment and nuclear translocation [58,59,60,61,62]. A detailed
understanding of this process may provide a future understanding
of TDP-43 pathology.
TDP-43 has been found to functionally interact with both
hnRNP A1 and hnRNP A2/B1 [63]. Although TDP-43
changed its subcellular localization upon MG-132 treatment,
that of the closely related nuclear factors hnRNP A1 and
hnRNP A2/B1 was not altered, suggesting that the interaction
is disrupted during the redistribution of TDP-43. This may
Figure 6. TDP-43 reduction increased vulnerability of neurons. (A) Immunocytochemistry of nuclear TDP-43 in neurons expressing control
(siR co) or two different siRNAs against TDP-43 (siR #543 and siR #560). SiR #543 and more so siR #560 reduce TDP-43 levels. Propidium iodine (PI)
uptake indicates increased cell death in siR #560 neurons. DAPI counterstains nuclei. (B) Quantification of TDP-43 fluorescence intensity reveals a
4265.0% and 8862.2% reduction of TDP-43 levels with siR #543 and siR #560, respectively, compared to control (siR co) neurons (Student’s t test
P,0.05; *** indicates P,0.0001). Levels of TDP-43 are similar in siR co and wild-type (WT) neurons (n.s., not significant). (C) Western blotting confirms
reduction of TDP-43 levels with siR #543 and siR #560, compared to siR co and wild-type (WT) neurons. Actin serves as loading control. (D) Numbers
of PI positive neurons upon treatment with vehicle (DMSO) or MG-132 for 16 hours. Numbers of PI positive cells are similar in DMSO- and MG-132-
treated siR co neurons, as well as in DMSO-treated siR #543 cells (Student’s t test P,0.05; n.s., not significant). MG-132 treatment significantly
increases numbers of PI positive siR #543 neurons (P,0.0001). High numbers of PI positive siR #560 neurons (7961.5%) are also increased by MG-
132, with virtually all cells being PI positive (9861.4%; *** indicates P,0.0001). (E) MG-132 induces cytoplasmic accumulation (arrowheads) of TDP-43
in both siR co and siR #543 neurons. Note the faint staining in siR #543 neurons due to reduced TDP-43 levels.
doi:10.1371/journal.pone.0022850.g006
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been shown that disruptions to the interactions between TDP-
43 and the hnRNP complex interferes with splicing processes
[63]. Similar to the hnRNPs, FUS remained within the nucleus
in MG-132-treated neurons. These differences in the re-
localization of nuclear proteins following proteasome inhibition,
may indicate that TDP-43 is shuttled at a much higher rate
between the nucleus and cytoplasm, which in turn may cause it
to become more prone to cytoplasmic accumulation in cells
with a dysfunctional proteasome.
Proteasome dysfunction has been implicated in several neuro-
degenerative disorders, including ALS [43,46]. Consistent with
our findings, proteasome inhibition resulted in the accumulation of
insoluble full-length TDP-43 together with fragments, in lympho-
blastoid cells isolated from patients carrying TARDBP mutations
[18,20]. Furthermore, studies using a range of immortalized cell
lines expressing either wild-type or mutant TDP-43 suggested that
proteasome inhibition accelerates TDP-43 accumulation and
insolubility [20,40,64,65,66]. Hence, approaches using protea-
some inhibitors provide valuable insights into the effects of TDP-
43 mislocalization and insolubility. Since neurons are the primary
cell type affected in FTLD-U and ALS, we tested the effects of
proteasome inhibition on endogenous TDP-43 in primary cortical
and hippocampal neurons or immortalized motor neurons.
Interestingly, we found that proteasome inhibition appears to
have much greater effects on TDP-43 localization and solubility in
primary neurons compared to the immortalized motor neurons.
This may result from neurons being postmitotic, while immortal-
ized cell lines undergo cell division that could compensate for cell
damage/death.
A common effect of treatments that lead to TDP-43 pathology
in cell culture models (e.g. TDP-43 fragmentation or subcellular
re-distribution) is that they also induce cell death, which is
sometimes not taken into account. Hence, the question remains as
to whether the induction of the TDP-43 pathology is a result of cell
death (or pathways that co-induce cell death and TDP-43
pathology), or alternatively, that the TDP-43 pathology contrib-
utes to the cell toxicity. Also in our study, we cannot fully exclude
that cell death is accompanied by TDP-43 re-localization,
however, these changes were observed prior to detection of
cellular toxicity. Furthermore, moderately reducing TDP-43 levels
in primary neurons via siRNA increased their vulnerability to
MG-132 treatment significantly, while only strong reduction of
TDP-43 levels by siRNA induced cell death on its own.
Knockdown of TDP-43 induces cell death in Neuro-2a cells
possibly through Rho family GTPases [67]. However, the exact
molecular mechanisms underlying TDP-43 pathology-induced
toxicity in neurons remain to be identified. To this end, our data
indicates that loss of TDP-43 function contributes to neurodegen-
eration, and makes neurons more vulnerable to second hits, such
as proteasome dysfunction.
In summary, we showed that proteasome inhibition by MG-
132 in primary neurons and the NSC-34 motor neuron cell line
is sufficient to induce cytoplasmic accumulation, aggregation,
fragmentation and insolubility of TDP-43, bearing similarities
to the TDP-43 pathology in FTLD-TDP and ALS. Reducing
TDP-43 levels exacerbated the toxic effects of MG-132-induced
proteasome inhibition in cultured neurons. Therefore, our data
support a second hit hypothesis in addition to TDP-43
dysfunction in these diseases. Furthermore, our data suggest
that the subcellular distributiono fT D P - 4 3u n d e rp h y s i o l o g i c a l




Human brain samples were obtained from the Australian Brain
Bank Network and the Department of Pathology of the University
of Zurich, Switzerland, with approval from the Human Ethics
Review Committee of the University of Sydney and the Zurich
University Hospital Research Ethics Committee. Written consent
from donors or donors next of kin for brain donation was received
by each brain bank. Immunohistochemical staining was carried
out as previously described [68].
Cell culture
All animal experiments have been approved by the Animal
Ethics Committee of the University of Sydney (approval number
K00/1-2010/3/5186). Primary hippocampal and cortical cultures
were prepared as previously described [51]. Briefly, hippocampi
and cortices from E16.5 mouse embryos were harvested,
trypsinized and dissociated in HBSS containing 1mg/ml DNase
and trypsin (Sigma) at 37uC for 20 minutes. For immunocyto-
chemistry, 200 000 cortical cells were plated in 10% FBS/DME
(Hyclone) in a ring around 2500 hippocampal or cortical cells on
12 mm glass coverslips coated with poly-D-lysine (Sigma). This
cortical ring provides neurotrophic support for the hippocampal
cells. For Western blotting 2610
6 cortical cells were plated on
10 cm culture dishes. 2 hours after cells have attached, the plating
medium was exchanged to Neurobasal medium supplemented
with B-27 supplement and Glutamax (all Gibco).
The immortalized motor neuron cell line NSC-34 was cultured
as previously described [52]. For Western blotting and cell
counting, 1610
6 NSC-34 cells were plated on 10cm culture dishes
and maintained in medium containing high glucose DME (Gibco,
Invitrogen, USA) supplemented with 10% FBS (Hyclone, USA),
2 mM L-glutamine and penicillin/streptomycin (Gibco).
Cell culture treatments
Primary hippocampal and cortical cultures were treated with
5 mM MG-132 (Calbiochem, Merck), 10 mM lactacystin (Calbio-
chem), 20 mM thapsigargin and 100 mg/mL tunicamycin (both
Sigma) after 20 DIV for up to 60 hours. These compounds were
dissolved in DMSO to yield stock solutions. For all subsequent
treatments, the compounds and DMSO were further diluted in
Neurobasal/B-27 medium and added to cultures to the indicated
final concentrations. For treatment with 5 mMH 2O2,1 mM
NMDA and 50 nM staurosporine (all Sigma), the compounds
were dissolved in either sterile water (H2O2 and NMDA) or
DMSO (staurosporine) to yield stock solutions, and for all
subsequent treatments further diluted in Neuralbasal/B-27
medium. Treatments with these particular compounds were
added directly to the culture medium for 1 hour, after which the
medium was removed, the cultures washed once with culture
medium, and then replenished with fresh Neuralbasal/B-27
medium and were then continued to be cultured for the indicated
amount of time. For vehicle controls, the according final dilution
of DMSO was used.
Prior to treatment with MG-132, the NSC-34 cells were treated
with Mitomycin C (Sigma) at a final concentration of 10 ug/mL
for 2.5 hours to arrest cell division. As for primary cultures, stock
solutions of MG-132 and DMSO were dissolved in culture
medium and cells treated at the indicated concentrations. For cell
counting, cell were washed once with pre-warmed PBS to remove
any unattached cells, and stained with 0.4% trypan blue solution
(Sigma).
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Once the cultures had been treated for the required amount of
time, the cells were washed once with pre-warmed PBS and fixed
with 4% paraformaldehyde for 15 min at room temperature.
Fixed cells were permeabilized with 0.2% Triton X in PBS for 5
minutes and blocked for 1 hour in 3%BSA/2% heat-inactivated
goat serum (Sigma) in PBS. Cells were stained overnight at 4uC
with primary antibodies to: TDP-43 (1:400, Proteintech),
phosphorylated TDP-43 Ser403/4 (1:1000, CosmoBio) hnRNP
A1 and hnRNP A2/B1 (1:200, Sigma), neurofilament (1:200,
Abcam), MAP2 (1:200, Sigma) FUS (1:200, Proteintech) and b3
tubulin (1:300, Covance). Nuclei were visualized with DAPI
(1:1000, Molecular Probes). Secondary antibodies (1:250,
Invitrogen) were coupled with the fluorochromes Alexa Fluor
555 (mouse) and 488 (rabbit). All antibodies were diluted in
blocking buffer. Dead cells were visualized by uptake of
propidium iodide (Sigma) that had been added to the cell
culture medium 5 min prior to fixation [48]. Pictures were taken
with a BX51 microscope (Olympus). Fluorescence intensity was
quantified using the Image J software (NIH). Intact cortical
neurons were counted on images collected from random fields
and normalized to the total cell number.
Subcellular fractionation
Subcellular fractionation of primary cortical cells (20 DIV)
treated with MG-132 or DMSO was carried out as previously
described [49]. Cells were washed once with pre-warmed PBS,
harvested and lysed with hypotonic buffer (10 mM HEPES
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM
DTT and Roche Complete Protease Inhibitors). After 20 minutes
incubation on ice, cells were homogenized 5 times with 0.3 ml
Insulin syringes. Homogenates were centrifuged at 500 g for 5
minutes to isolate nuclei. The cytoplasmic supernatant was re-
centrifuged at 500 g for 5 minutes to remove any contaminating
nuclei. The nuclei pellets were resuspended in high salt buffer
(20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT and protease inhibitors) and incubated on ice
for 20 minutes. This homogenate was centrifuged at 14000 rpm
for 10 minutes, at 4uC, to obtain the nuclear supernatant. The
pellet was resuspended in urea buffer (7 M urea, 2 M thiourea,
4% CHAPS, 30 mM Tris, pH 8.5), sonicated at 30% amplitude
and centrifuged at 14000 rpm. The supernatant obtained is the
insoluble fraction.
Protein extraction
Proteins were extracted from both primary cortical neurons and
NSC-34 cells as previously described [50]. Cells were washed once
with pre-warmed PBS, harvested and then lysed with ice-cold,
modified RIPA buffer (with Roche Complete Protease Inhibitors,
20 mM MOPS (pH 7.0), 1% (v/v) TritonX100, 0.25% Na-
deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EGTA, 5 mM
EDTA, 30 mM NaF, 60 mM b-glycerophosphate, 20 mM Na-
pyrophosphate, 1 mM Na3VO4,5mM Pepstatin A, 1 mM DTT).
The samples were then sonicated at 30% amplitude and
centrifuged at 50,000 g for 60 min at 4uC. The supernatant was
collected as the soluble fraction. The resulting pellets were
resuspended in RIPA buffer, re-sonicated and re-centrifuged as
above twice more to remove any contaminating proteins. Only
supernatants from the first centrifugation were analyzed. The
remaining pellets were resuspended in urea buffer, sonicated at
30% amplitude and centrifuged at 50,000 g for 60 min at 4uC.
The supernatant obtained is the insoluble fraction.
Western blotting
Protein measurements of all obtained fractions were determined
by the Bradford assay. Protein extracts were analyzed by
immunoblotting, which was performed as previously described
[69,70]. Between 10–100 mg of proteins were loaded and
separated in 8–15% SDS-PAGE gels. Proteins were then
electrophoretically transferred onto nitrocellulose membranes
(Hybond, GE Healthcare). These membranes were subsequently
blocked with 5% bovine serum albumin (BSA) in Tris-buffered
saline containing 0.1% Tween 20 (TBS-T) at room temperature
for 1 hour, followed by incubation with the primary antibodies
diluted in 5% BSA/TBS-T overnight at 4uC while shaking.
Antibodies used were to: TDP-43 (1:1000, Proteintech), Hsp70
(1:1000, Stressgen), ubiquitin (1:2500, Dako), GAPDH (1:5000,
Millipore), a-actin (1:5000, Chemicon) and a-tubulin (1:5000,
Sigma) H2AX and phosphorylated H2AX (both 1:1000, Milli-
pore), phosphorylated TDP-43 at Ser403/404 and at Ser409/10
(both 1:1000, CosmoBio) and hnRNP A1 (1:1000, Sigma). After
removal of the primary antibody, the membranes were washed
with TBS-T and then incubated with alkaline phosphatase-
coupled secondary antibodies (mouse or rabbit IgG, Sigma) in
1% BSA/TBS-T (1:15 000) for 30 min at room temperature.
Protein bands were visualised with Immobilon Chemiluminescent
Alkaline Phosphatase substrate (Millipore) and detected in a
VersaDoc Model 4000 CCD camera System (BioRad). For
normalisation, the membranes were stripped by washing with
dH2O for 5 min, followed by 0.2 M NaOH for 10 min and dH2O
for 5 min before being reprobed for GAPDH, a-actin and a-
tubulin. Quantification of bands was performed using BioRad
Quantity One 1-D analysis software v4.6 (BioRad).
Immunoprecipitation
IPs were carried out as previously described [71] using a TDP-
43-specific antibody produced in rabbit (Proteintech) for copreci-
pitation with ubiquitin in IP buffer (50 mM Tris-HCl (pH 8.0),
150 mM NaCl, 1% Nonidet P-40 substitute (all Sigma), and
complete EDTA-free protease inhibitor mixture (1 tablet in
40 mL; Roche). Antibodies were pulled down with magnetic
Dynabeads Protein G (Invitrogen) and washed four times with IP
buffer before eluting with sample buffer for SDS-PAGE.
AP treatment
Protein samples were incubated with calf intestine AP (Takara,
final concentration of 0.28 units/mL) in the corresponding AP
buffer (50 mM Tris-HCl (pH 9.0), 1 mM MgCl, and Complete
Protease Inhibitor (Roche)) at 37uC for 2 hours while shaking.
Once complete, sample buffer was added and the samples
analysed by Western blotting.
Lentiviral production
For lentiviral production, 293T human embryonic kidney cells
were used to generate lentiviral packaging, whilst SH-SY5Y cells
were used for tittering of viral stocks, as previously described [72].
After 7 DIV, the medium was removed from the primary cultures
and replaced with lentiviruses diluted in Neuralbasal/B-27. After 3
days of incubation with the lentivirus the medium was replaced
with fresh Neuralbasal/B-27, and after another 5 days the cells
were then treated with either 5 mM MG-132 or DMSO for the
appropriate amount of time.
Statistics
Statistical analysis was performed with the Prism 5.0 software
(Graph Pad, USA). All values are given as mean 6 SEM.
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Figure S1 Effects of different treatments on primary neurons. (A)
Western blot analysis reveals similar levels of H2AX upon all
treatments: vehicle (DMSO), NMDA (1 mM), H2O2 (5 mM),
staurosporine (50 nM), MG-132 (5 mM), lactacystin (10 mM),
thapsigargin (TG; 20 mM) and tunicamycin (TM; 100 mg/mL).
While H2AX is not phosphorylated in vehicle-treated neurons, all
other treatments caused a similar degree of phosphorylation of
H2AX, a non-specific marker of cell death, at chosen doses. (B)
Only MG-132 and lactacystin induce expression of Hsp 70 and
high levels of ubiquitination, indicating proteasome dysfunction.
(TIF)
Figure S2 Progressive insolubility of TDP-43 upon proteasome
inhibition in the immortalized motor neuron cell line, NSC-34. (A)
RIPA and subsequent urea extraction of proteins from MG-132
(5mM) and vehicle (DMSO) treated NSC-34 cells. TDP-43
(arrowhead) and its fragments (*) reduce in the RIPA-soluble
fractions over 48 hours, whereas TDP-43 is unchanged in vehicle
treated controls. Note the presence of soluble TDP-43 fragments
in controls. In parallel, TDP-43 increased in the insoluble (Urea)
fractions of MG-132 treated neurons together with fragments (*), a
distinct 45kD species (1) and high molecular weight aggregates (#).
(B) Consistent with proteasome inhibition by MG-132, levels of
the heat-shock protein 70 (Hsp70) increases with time. (C)
Similarly, the amount of insoluble highly ubiquitinated proteins
increased progressively upon MG-132 treatment. Representative
Western blots from three experiments are shown. (D) NSC-34 cell
viability during proteasome inhibition. The number of attached
viable NSC-34 cells was similar upon vehicle (DMSO) and MG-
132 treatment up to 36 hours, while a significant decrease became
only obvious after 48 hours (*P,0.01; n=6). (E) Phosphorylation
of insoluble TDP-43 from MG-132-treated NSC-34 cells as shown
by molecular weight shift upon dephosphorylation with alkaline
phosphatase (AP). Accordingly, TDP-43-reactive bands of ap-
proximately 45kD (1) and the high molecular weight smear (#)
collapsed to 43kD. (F) Immunoprecipitation (IP) with an antibody
to TDP-43 and subsequent detection with an antibody to ubiquitin
shows the high degree of ubiquitination of the high molecular
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